ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic repurposing framework target for metabolic dysfunction-associated steatohepatitis patients - Top-Institutions - MDSpire

ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic repurposing framework target for metabolic dysfunction-associated steatohepatitis patients

  • By

  • Guiying Zeng

  • Qi Zhao

  • Li Jiang

  • Dongmei Xie

  • Lin Du

  • Mei Yang

  • Mei Luo

  • Qian Wang

  • July 7, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Gastroenterology
    • Hepatology

  • #2

    The Mount Sinai Hospital
    The Mount Sinai Hospital

    New York, New York

    Key Differentiators

    • Gastroenterology
    • Hepatology

  • #3

    European Association for the Study of the Liver
    European Association for the Study of the Liver

    N/A, N/A

    Key Differentiators

    • Gastroenterology

  • #4

    Japan Society of Gastroenterology
    Japan Society of Gastroenterology

    N/A, N/A

    Key Differentiators

    • Gastroenterology

  • #5

    American Association for the Study of Liver Disease
    American Association for the Study of Liver Disease

    N/A, N/A

    Key Differentiators

    • Gastroenterology

Original Source(s)

ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic repurposing framework target for metabolic dysfunction-associated steatohepatitis patients

  • by Guiying Zeng, Qi Zhao, Li Jiang, Dongmei Xie, Lin Du, Mei Yang, Mei Luo, Qian Wang

  • July 7, 2026

Related Content

Editorial: AI-driven smart sensing and processing for personalized healthcare

Immediate prediction of post-ERCP pancreatitis: a novel approach using serum trypsin

The gut microbiota as a potential determinant of response to GLP-1 receptor agonists: a narrative review